"Designing Growth Strategies is in our DNA"

Antidepressants Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Selective Serotonin Reuptake Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical Antidepressants, Tricyclic Antidepressants), By Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2020-2027

Region : Global | Format: PDF | Report ID: FBI105017

 

Table of Content:

  1. Introduction
    1. Market Scope
    2. Market Segmentation
    3. Market Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Prevalence of Anxiety & Depression –Key Regions/Country
    2. New Product Launch
    3. Pipeline Analysis
    4. Impact of COVID-19 on the Antidepressants Market
    5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  5. Global Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Geography
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      2. Canada
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
  7. Europe Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      2. Germany
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      3. France
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      4. Spain
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      5. Italy
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      6. Scandinavia
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      7. Rest of Europe
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
  8. Asia Pacific Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Japan
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      2. China
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      3. India
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      4. Australia
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      5. Southeast Asia
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
      6. Rest of Asia Pacific
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
  9. Latin America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      2. Mexico
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      3. Rest of Latin America
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
  10. Middle East & Africa Antidepressants Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Selective Serotonin Reuptake Inhibitors (SSRIs)
      2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      3. Atypical Antidepressants
      4. Tricyclic Antidepressants (TCAs)
      5. Monoamine Oxidase Inhibitors (MAOIs)
      6. Others
    3. Market Analysis, Insights and Forecast – By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      2. South Africa
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
      3. Rest of Middle East & Africa
        1. By Disorder
          1. Major Depressive Disorder
          2. Obsessive Compulsive Disorder
          3. Generalized Anxiety Disorder
          4. Panic Disorder
          5. Others
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2019)
    3. Company Profiles (Overview, Drug Class, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. H. Lundbeck A/S
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. GlaxoSmithKline plc
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Eli Lilly and Company
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Janssen Pharmaceuticals
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Pfizer Inc.
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. Merck & Co. Inc.
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. AztraZeneca
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. Bristol-Myers Squibb
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      10. Other Prominent Players
        1. Overview,
        2. Drug Class,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  12. Strategic Recommendations

List of Figures

Figure 1:  Global Antidepressants Market Revenue Breakdown (USD billion, %) by Region, 2019 & 2027

Figure 2:  Global Antidepressants Market Value Share (%), by Drug Class, 2019 & 2027

Figure 3:  Global Antidepressants Market Forecast (USD billion), by Selective Serotonin Reuptake Inhibitors (SSRIs), 2016-2027

Figure 4:  Global Antidepressants Market Forecast (USD billion), by Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), 2016-2027

Figure 5:  Global Antidepressants Market Forecast (USD billion), by Atypical Antidepressants, 2016-2027

Figure 6:  Global Antidepressants Market Forecast (USD billion), by Tricyclic Antidepressants (TCAs), 2016-2027

Figure 7:  Global Antidepressants Market Forecast (USD billion), by Monoamine Oxidase Inhibitors (MAOIs), 2016-2027

Figure 8:  Global Antidepressants Market Forecast (USD billion), by Others, 2016-2028

Figure 9:  Global Antidepressants Market Value Share (%), by Disorder, 2019 & 2027

Figure 10:  Global Antidepressants Market Forecast (USD billion), by Major Depressive Disorder, 2016-2027

Figure 11:  Global Antidepressants Market Forecast (USD billion), by Obsessive Compulsive Disorder, 2016-2027

Figure 12:  Global Antidepressants Market Forecast (USD billion), by Generalized Anxiety Disorder, 2016-2027

Figure 13:  Global Antidepressants Market Forecast (USD billion), by Panic Disorder, 2016-2027

Figure 14:  Global Antidepressants Market Forecast (USD billion), by Others, 2016-2027

Figure 15:  Global Antidepressants Market Value Share (%), by Distribution Channel, 2019 & 2027

Figure 16:  Global Antidepressants Market Forecast (USD billion), by Hospital Pharmacy, 2016-2027

Figure 17:  Global Antidepressants Market Forecast (USD billion), by Retail Pharmacy, 2016-2027

Figure 18:  Global Antidepressants Market Forecast (USD billion), by Online Pharmacy, 2016-2027

Figure 19:  Global Antidepressants Market Value (USD billion), by Region, 2019 & 2027

Figure 20:  North America Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 21:  North America Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 22:  North America Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 23:  North America Antidepressants Market Value Share (%), by Disorder, 2019

Figure 24:  North America Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 25:  North America Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 26:  North America Antidepressants Market Value (USD billion), By Country, 2019 & 2027

Figure 27:  North America Antidepressants Market Value Share (%), By Country, 2019

Figure 28:  Europe Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 29:  Europe Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 30:  Europe Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 31:  Europe Antidepressants Market Value Share (%), by Disorder, 2019

Figure 32:  Europe Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 33:  Europe Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 34:  Europe Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 35:  Europe Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 36:  Asia Pacific Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 37:  Asia Pacific Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 38:  Asia Pacific Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 39:  Asia Pacific Antidepressants Market Value Share (%), by Disorder, 2019

Figure 40:  Asia Pacific Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 41:  Asia Pacific Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 42:  Asia Pacific Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 43:  Asia Pacific Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 44:  Latin America Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 45:  Latin America Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 46:  Latin America Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 47:  Latin America Antidepressants Market Value Share (%), by Disorder, 2019

Figure 48:  Latin America Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 49:  Latin America Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 50:  Latin America Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 51:  Latin America Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 52:  Middle East & Africa Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 53:  Middle East & Africa Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 54:  Middle East & Africa Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 55:  Middle East & Africa Antidepressants Market Value Share (%), by Disorder, 2019

Figure 56:  Middle East & Africa Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 57:  Middle East & Africa Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 58:  Middle East & Africa Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 59:  Middle East & Africa Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 60:  Global Antidepressants Market Share (%), By Company, 2019

List of Tables

Table 1:  Global Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016–2027

Table 2:  Global Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016–2027

Table 3:  Global Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016–2027

Table 4:  Global Antidepressants Market Revenue (USD billion) Forecast, by Region, 2016-2027

Table 5:  North America Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 6:  North America Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 7:  North America Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 8:  North America Antidepressants Market Revenue (USD billion) Forecast, By Country, 2016-2027

Table 9:  Europe Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 10:  Europe Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 11:  Europe Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 12:  Europe Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 13:  Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 14:  Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 15:  Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 16:  Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 17:  Latin America Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 18:  Latin America Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 19:  Latin America Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 20:  Latin America Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 21:  Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 22:  Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 23:  Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 24:  Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

 

 class=
  • Mar, 2021
  • 2019
  • 2016-2018
  • 135

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X